Connect with us

featured

Top Marijuana Advocate Who Led Fight For State Legalization Ballot Measures Is Departing To Focus On Preserving Citizen Initiative Process

Published

on


If states are the laboratories of democracy, Matthew Schweich has been a top chemist at the Marijuana Policy Project (MPP), playing a pivotal role in multiple campaigns to put medical and adult-use cannabis legalization measures on the ballot in politically diverse states—from Massachusetts to Utah.

But after 10 years at the national organization—widely considered one of the most effective proponents of reform at the state and federal level over its decades of work—Schweich is hanging up his hat. Or hats. While he focused much of his energy on state ballot initiatives, the advocate was also entrusted to helm the ship as interim executive director at various intervals throughout his tenure.

From an outside perspective, it’s somewhat easy to imagine that affecting change on cannabis policy, and getting voters to rally behind legalization, would be a relatively uncomplicated lift. After all, polls consistently show majority (and increasingly bipartisan majority) support for the reform. But the work to achieve those success at the polls is no small task—something Schweich has come to understand well.

It’s also a task that’s become all the more complicated in recent years. With the vast majority of states having legalized cannabis in some form, including nearly half of the country with recreational legalization on the books due in no small part to the advocacy of organizations like MPP, the once robust grassroots movement fueled largely by philanthropic support, has tapered.

It’s that complacency, coupled with an aggressive push to restrict the ability of voters to make decisions on marijuana laws themselves at the ballot in certain state, that gives Schweich pause as he leaves his post. With an end to federal prohibition seemingly within reach, he worries that the lack of attention and funding for state ballot efforts could extend the state-federal policy disconnect indefinitely.

“I just sense that we’ve been taking our foot off the gas,” he told Marijuana Moment. “We need to finish this fight. We haven’t finished it yet.”

To be sure, there are lingering uncertainties about the fate of cannabis reform under President Donald Trump’s second term. The so-far unrealized goal of rescheduling marijuana under a process initiated under the Biden administration has put a fine point on that. And despite Trump’s endorsement of the reform—as well as cannabis industry banking access—he’s been notably silent on the issue since taking office, leaving room for speculation about whether the White House views it as a priority.

If there’s a chance to reach what Schweich calls the “holy grail” of federal legalization, that power has always sat with the states. Red or blue or purple, lawmakers who represent states that legalize cannabis are confronted with the reality that their constituents are ready for a change. Schweich, who is now pivoting to a project where he’s working to defend the citizen initiative process, was a key actor in effectuating that change.

“I hope that we can regain momentum and regain focus and continue the work at the state level—because that’s ultimately what’s going to deliver federal reform: maintaining pressure at the state level.”

Schweich spoke to Marijuana Moment about his role at MPP, the state of the cannabis reform movement and more. The following interview has been lightly edited for length and clarity.

Marijuana Moment: Where did your passion for marijuana policy reform come from?

Matthew Schweich: I’ve just always found the irrationality of making alcohol legal and cannabis illegal intolerable. I’ve always been angry by that inconsistency and all the suffering and harm that it’s inflicted on our society. I’ve long believed that we have a problem in America with how we criminalize our own people and also how we imprison them.

Of all the unjust ways we criminalize people, cannabis prohibition is by far the least defensible, so cannabis legalization always seemed like a way to take a big step in the right direction when it comes to the criminalization and incarceration the American people.

MM: How would you characterize the role of MPP in advance reform to date?

MS: MPP has been instrumental for the 10 years I’ve been there—not just with our ballot initiative victories, but our legislative victories as well. I came to fully understand the benefit of institutional knowledge within a reform movement, and MPP has been that source of institutional knowledge, taking lessons learned from one state—whether it’s with a ballot initiative campaign or a legislative campaign—and applying those in other states, while still shaping the policy to each state.

That requires a national organization that’s plugged in all across the country. And that’s what MPP has been doing for 30 years now.

I always enjoyed the challenge of going to a new state, meeting the people on the ground and finding the right blend of using successful tactics that have that have been effective in other states with the local flavor, and incorporating the input of of the people who know that state.

That’s been a balancing act that I’ve found interesting and stimulating throughout my time at MPP, because you can’t be on either end of the spectrum. You can’t try a strategy without looking at what’s worked elsewhere. And you also can’t go in with a cookie-cutter approach. And a big part of my job has been blending those two things in the right way.

MM: More broadly, where do you see the reform movement going over the coming years?

MS: I am concerned that we’re taking our foot off the gas. You know, when I walk through the MPP office, there’s a wall full of books about the war on drugs—the war on cannabis. And it’s strange to me when you look at how much thought and energy was directed into this movement long before it had a single victory anywhere.

Now we’ve had all these victories, and we’re within striking distance of the holy grail—which is fixing this at the federal level, achieving federal cannabis legalization—and yet it seems difficult for us to maintain people’s attention and commitment.

That’s been frustrating, the last few years, to watch. I just sense that we’ve been taking our foot off the gas, and it seems a shame that if we made all this progress at the state level but then we allow this ridiculous federal policy to persist for many years to come.

We need to finish this fight. We haven’t finished it yet, and there’s still some very large-population states where cannabis is illegal, like Florida and Texas. So I hope that we can regain momentum and regain focus and continue the work at the state level—because that’s ultimately what’s going to deliver federal reform: maintaining pressure at the state level.

MM: To what extent do you think this growing complacency is attributable to the fact that advocates have secured victories in so many states over recent years?

MS: To a certain extent, we’re victims of our own success, because we have achieved so many victories at the state level on both recreational cannabis and medical cannabis, and those victories have occurred in states where voters are more inclined to support legalization.

A lot of people in the country now live in a state that’s got either recreational or medical cannabis legalized who don’t feel this has some urgency, and I do think that’s a contributing factor.

Also, I think another factor is just how turbulent our political climate has become. There’s a sense among many people that we’re facing existential attacks on the very structure—our very democracy itself. And so I think those types of concerns were really not that prevalent 10 or 15 years ago. That pulls energy away from issues like ours.

MM: We’ve seen an uptick on attacks on the citizen ballot initiative process in several states. How concerned are you about that trend? And do you think the success of marijuana policy reform at the polls motivated some of these efforts?

MS: It’s very concerning to see all these different attacks. I’ve been on the front lines of this, as relates to cannabis, and I’m seeing attacks on the initiative process all over the country. I believe the initiative process is a very good thing for the states that have it. It gives the people a way to enact policies when their elected officials don’t listen. And in a very partisan, red-blue political climate, it’s difficult to push your state legislature to enact certain policy on cannabis when everything seems to get filtered through this red-blue lens.

The hyper-partisan nature of politics in this country means that state legislatures are less responsive to the will of the people than I think they’ve been ever, or for a very long time, which makes the initiative process really important.

And I’ve seen the attacks firsthand. In South Dakota, we passed Amendment A, which is recreational cannabis legalization, with 54 percent of the vote—and it was overturned by the South Dakota Supreme Court on a single-subject challenge, which I think was a deeply flawed decision.

In Nebraska, we were about to be on the ballot, and before voters could vote in 2022, but that medical cannabis policy was thrown off the ballot due to a single-subject challenge. So I’ve experienced and been a victim of these attacks.

I don’t think it’s solely a response to the success of cannabis reform that we’re seeing these attacks on the initial process. I think cannabis is a contributing factor, but there’s other issues—like Medicaid expansion that state legislatures in red states were deeply opposed to and where voters overwhelmingly support it. There’s also been a lot of activity in terms of reproductive rights on the ballot ever since Roe vs. Wade was overturned.

So I think it’s a number of issues that have bothered state legislators. They see these as undermining their ability to make all the policy decisions in the state, regardless of what the people want.

Part of what we’re seeing in terms of these attacks on the initiative processes is a result of a disintegration of political norms in the past. We didn’t see these types of attacks in the initiative process 20 or 30 years ago at this frequency. There seems to be a degree of shamelessness now when it comes to many state legislators. They don’t see any real negative potential effect of supporting these attacks to the initiative process, and I think it’s just a decline of our general respect for political norms in this country, which we’ve witnessed over the last seven to eight years.

MM: As I’ve covered these issues, one thing that’s stood out to me are the comments from officials who seem to be implying the electorate can’t be trusted to understand what’s being presented to them on the ballot.

MS: I agree. In the past, I think that there was a certain level of respect afforded to decisions made by the electorate. These days, politicians are very quick to dismiss the results of ballot questions. Again, I just think it’s a behavior that’s been normalized when you’ve got a president making completely unfounded claims about the outcome of an election, or completely misrepresenting what occurred on January 6. It shouldn’t be a surprise that other politicians now feel that they have the latitude to question other types of electoral results. They’re just questioning them in a different way.

We’ve entered an era where it is acceptable behavior to question elections and what they mean. In the past, I think that there was a there was a general understanding that we should respect election results—whether it’s with candidates or ballot questions. And what you also often hear now is politicians saying, ‘Well, people didn’t know what they were voting on. They didn’t understand the initiative.’ I think that’s really disrespectful to voters.

MM: The cannabis industry has faced criticism over the perception it is not doing enough to financially support state legalization initiatives that they’ve benefitted from, especially as philanthropic support for reform efforts has dried up over the years. What’s your take on that?

MS: I’ve long described the challenge of fundraising for cannabis reform to be a tragedy of the commons within another tragedy of the commons. By that I mean, in the early days, it was philanthropists funding cannabis reform because there was no industry—because there was no legal cannabis.

Then after a few victories on the medical side and then the recreational side, we start to see an industry emerge. And this is the first tragedy of the commons, with the philanthropist saying, ‘Well, why should we have to continue to support this? There’s an industry that we helped create through our philanthropy. Can’t they now be the source of funding this reform work?’ And then within that, within the industry, you’ve got all the companies pointing at each other saying, ‘Well, why should I help when my competitors aren’t?’ So that has been the fundamental challenge, in my opinion, for the past, really, 10 years.

I think it’s fair to critique the industry, given how much money was wasted, in my opinion, on premature federal reform efforts. And even in the last several years, we’re seeing enormous amounts of money being being directed to Florida campaigns—huge sums—and at the same time, a very, very small amount by comparison being invested in every other state in the country. I don’t think it’s the most efficient use of resources.

At the same time, I have to point out, I’ve had many successful partnerships with the cannabis industry. They’ve been very strong supporters at times, and I’m very appreciative of those within the cannabis industry who I think were enlightened enough to see the bigger picture.

But I must say, with regard to the biggest companies, it’s been disappointing, in my opinion, in terms of what they’ve contributed to the movement. In my experience, it’s been the medium- and smaller-sized companies that have actually been stepping up to the plate.

MM: There are some who feel strongly that any movement on federal marijuana reform during Trump’s second term will be incumbent on his proactive advocacy. Do you share that view? What’s your sense of how things shake out on federal cannabis policy in the short-term?

MS: I maintain some sense of optimism that things could move. We could see significant movement at the federal level during this administration. Things can change very quickly in the Trump administration. Priorities could change quickly, and there’s still a lot of time. Also [Trump] very strongly supported the Florida campaign in 2024, and I also think he sees the political value of having the Republican party be the party that ends federal cannabis prohibition.

So for those political reasons, I think that there’s still a path to getting something done federally during this administration—but it’s not a given.

I think that maintaining pressure at the state level is the best path forward. We can’t just let the states lie quiet. We have to keep advocating for reform in state legislatures wherever we can so that more and more members of Congress represent constituencies where these policies are in place.

I think part of the challenge is that the Republican leadership in Congress is not at the same point where Trump has been on this issue. That could be something that proves difficult to overcome. And it’s also possible this is stalled out—that we’re going to have [Terrance Cole as] the new head of DEA. We’re not getting many good signs there. So I think there’s still a path, but it very well could be the case that nothing major occurs in the next several years.

MM: Thinking back to when you started working for MPP 10 years ago, did you imagine we’d be at this point, further ahead or further behind on the cannabis policy front?

MS: I think I would have expected about where we’re at. As you know, I’ve long been a pessimist on federal reform—and I’ve been proven right over and over again. I always thought that it would really be a struggle to get this across the finish line at the federal level, so that matches up in terms of the number of states where we’ve passed these policies. It makes sense to me.

When I first joined, I was looking at the polls for our campaigns in Maine and Massachusetts and Arizona—and I saw the polling numbers in this diverse collection of states and figured, ‘Wow, the support is really there. Then we did medical cannabis in Utah in 2018. That’s probably the most surprising thing that I’ve done. It reinforced my belief that medical cannabis could be passed anywhere. So early on, it was clear that there was a major gap between where politicians were and where voters were. So I think we’re about where I would have guessed we’d be at this point.

MM: Are there any specific memories that stand out to you from your tenure at MPP?

MS: The first is in Maine in the winter of 2016. We’re finishing up the signature drive. It was the last day—and in Maine, you have to deliver your petitions to local election clerks. You don’t bring them all to the secretary of state like to do in other states. We were trying to squeeze every last signature out of the signature drive, and we had stacks of petitions with voters from different towns and different places. And we coordinated—I think it could have been in a movie—we coordinated this meet-up at a gas station with three different cars arriving with various stacks of petitions, and we stood in this parking lot of a gas station exchanging paper, frantically jumped back in our cars and then each had a route of towns to hit to drop off petitions before the four o’clock deadline. It was just this very fun and exciting moment in a signature drive.

There’s something very appealing about signature drives to me. A lot of people would hear that statement and think I’m crazy. But I love signature drives because you talk to voters and you force people to interact with their democracy beyond just voting—and you make them think about a policy. It’s not just like, ‘Oh, show up at the polls every year, every two years or every four years. It’s a conversation about a matter of public policy where you, the individual, have the power to bring this decision to everyone. I think there’s something special about that. And also, in working in politics, you’re staring at a screen on your computer like many of us are. But when you’re out collecting signatures, you can pick up that stack of petitions at the end of the day and feel the hard work that you’ve put in.

The other memory is just being in D.C. at a happy hour with my MPP colleagues. When I first joined, the office was teeming with people. There was a real office culture, and we all shared this sense that we were fortunate to get to work on cannabis reform. And it was just a really great group of people that evolved over time, and we were tucked away in Adams Morgan—which people that know D.C. will know that that’s really not a typical place to have an office right there on 18th street. It’s a neighborhood with real character. We were an office with real character, and we went together well. And I just remember the sense of camaraderie, and I think a lot of people can relate to this. When COVID came, it just killed so many office cultures, and I’ll always be thankful that I got to experience a really special and supportive and loving office culture in D.C. as we worked with people all over the country to make positive change.

So those are two memories that stick out.

MM: What can you share about what you’re doing next in your career?

MS: My plan is to work on a new project to defend the initiative process itself. During my time at MPP, I’ve been lucky to work in states all over the country on ballot initiatives, and I’ve come to learn how diverse these processes are—different sets of rules, different petition designs, different procedures for submitting them and validating them and challenging them. And so I’ve learned through all these election cycles working on cannabis policy just how intricate and unique these ballot initiative processes can be. At the same time, I’ve seen firsthand the attacks on these processes.

I found at MPP the incredible value of there being a national organization with the institutional knowledge that’s sharing lessons between states. And I think we need the same thing for defending the initiative process. So that’s what I’ve been working on in South Dakota so far. I have a group there called the Voter Defense Association of South Dakota, and I’m hoping to replicate that in other states and take all the lessons I learned from the cannabis legalization ballot initiatives and apply them to the preservation of the initiative process itself.

It’s something that future generations of voters can use to effectuate positive changes in public policy on a range of issues. What we’re witnessing right now is a breakdown in our political culture as a country. I think what we’ve also witnessed is the failure of political parties to put forward the right types of candidates for voters to decide. That applies equally to the Democratic and Republican parties, and I think now more than ever we need to maintain tools to fix public policy that don’t require the approval of elected officials. I have less respect for our collection of elected officials all across the country than I did in the past.

I hope it gets better. I still respect their positions and authority. I believe in that sense of decorum and respect. But in terms of their policymaking decisions, I’m fairly appalled on a range of issues all over the country. To me, the quality of our elected officials has gone down in recent years, which means that to fix public policy, we need tools like the initiative process. Working on these cannabis campaigns really made me a very big believer in the positive potential of ballot initiatives.

Far-Right Trump Ally Takes Aim At New Psychedelics-Focused Hire At Federal Health Agency

Marijuana Moment is made possible with support from readers. If you rely on our cannabis advocacy journalism to stay informed, please consider a monthly Patreon pledge.

Become a patron at Patreon!





Source link

mscannabiz.com
Author: mscannabiz.com

MScannaBIZ for all you Mississippi Cannabis News and Information.

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

featured

Trump’s VA Head Visits Psychedelics Research Center, Reiterating ‘Promise’ To Explore Benefits For Military Veterans

Published

on


The head of the U.S. Department of Veterans Affairs (VA) visited a facility conducting research on psychedelics this week, reiterating that it’s his “promise” to advance research into the therapeutic potential of the substances—even if that might take certain policy changes within the department and with congressional support.

In a video shared on X on Tuesday, VA Secretary Doug Collins talked about his commitment to pursuing clinical trials into substances such as MDMA—standing alongside Rachel Yehuda, the director of mental health at VA’s James J. Peters Veterans Affairs Medical Center who has overseen and advocated for psychedelics research.

“I told you all along that we are looking at psychedelics. We’re looking at anything to help our veterans,” Collins said, while stressing that he acknowledges “there’s no silver bullet for the things we have for trauma and our stress and the incidences of childhood.”

“These are all things that come out in our veterans as they come back from war zones, but also just in everyday life. But you know, sitting here with Rachel and the doctors here, I have found that there’s some things that are working,” the secretary said. “I promised you that we’re going to look into this, and we’re making changes to make it even better so we can make it more available.”

“It’s going to take some change in the VA. It’s going to take some changes in Congress. But it’s a thing that I have said we want to do because we want to take care of veterans,” Collins said, noting that the room they filmed the video in is one of the facilities where MDMA clinical trials are currently underway.

“These are things we’re going to continue. I promise you, we’re going to do it,” he said, telling Yehuda to “keep doing what you’re doing because it is meaningful to our veterans, and I want to thank you.”

Yehuda shared the secretary’s post and said she was pleased to meet Collins and “show what we’ve built at [VA] for our veterans.”

“We’re excited about the expansion of our [Parsons Research Center for Psychedelic Healing] at the VA and the two new studies that have just begun here with MDMA and psilocybin,” she said.

Collins’s visit to the psychedelics research center comes about a month after the VA secretary met with a military veteran who’s become an advocate for psilocybin access to discuss the therapeutic potential of psychedelic medicine for the veteran community.

Collins also briefly raised the issue in a Cabinet meeting with President Donald Trump in April.

The secretary also disclosed in April that he had an “eye-opening” talk with U.S. Department of Health and Human Services (HHS) Secretary Robert F. Kennedy Jr. about the therapeutic potential of psychedelic medicine. And Collins said he’s open to the idea of having the government provide vouchers to cover the costs of psychedelic therapy for veterans who receive services outside of VA as Congress considers pathways for access.

During a recent Senate committee hearing, he separately reiterated his commitment to exploring the efficacy of psychedelic therapy to address serious mental health conditions that commonly afflict military veterans.

Meanwhile last month, bipartisan congressional lawmakers asked the VA head to meet with them to discuss ways to provide access to psychedelic medicine for military veterans.

In a letter sent to Collins, Reps. Lou Correa (D-CA) and Jack Bergman (R-MI)—co-chairs of the Congressional Psychedelic Advancing Therapies (PATH) Caucus—said they were “encouraged by your recent remarks about the importance of pursuing research into psychedelic treatments and other alternative treatments to improve Veterans’ care.”

Correa and Bergman separately introduced a bill in April to provide $30 million in funding annually to establish psychedelics-focused “centers for excellence” at VA facilities, where veterans could receive novel treatment involving substances like psilocybin, MDMA and ibogaine.

Bergman has also expressed optimism about the prospects of advancing psychedelics reform under Trump, arguing that the administration’s efforts to cut spending and the federal workforce will give agencies “spines” to tackle such complex issues.


Marijuana Moment is tracking hundreds of cannabis, psychedelics and drug policy bills in state legislatures and Congress this year. Patreon supporters pledging at least $25/month get access to our interactive maps, charts and hearing calendar so they don’t miss any developments.


Learn more about our marijuana bill tracker and become a supporter on Patreon to get access.

In December, VA separately announced that it’s providing $1.5 million in funding to study the efficacy of MDMA-assisted therapy for veterans with PTSD and alcohol use disorder (AUD).

Last year, VA’s Yehuda also touted an initial study the agency funded that produced “stunning and robust results” from its first-ever clinical trial into MDMA therapy.

In January, former VA Under Secretary for Health Shereef Elnahal said that it was “very encouraging” that Trump’s pick to have Kennedy lead HHS has supported psychedelics reform. And he hoped to work with him on the issue if he stayed on for the next administration, but that didn’t pan out.

Most Marijuana Consumers Oppose Trump’s Cannabis Actions So Far, But Rescheduling Or Legalization Could Bolster Support, Poll Shows

Photo elements courtesy of carlosemmaskype and Apollo.

Marijuana Moment is made possible with support from readers. If you rely on our cannabis advocacy journalism to stay informed, please consider a monthly Patreon pledge.

Become a patron at Patreon!





Source link

mscannabiz.com
Author: mscannabiz.com

MScannaBIZ for all you Mississippi Cannabis News and Information.

Continue Reading

featured

Lawmakers Could Reschedule Marijuana With ‘Greater Speed And Flexibility’ Than Administration Officials, Congressional Researchers Say

Published

on


Amid a stalled marijuana rescheduling process that’s carried over from the last presidential administration, congressional researchers are reiterating that lawmakers could enact the reform themselves with “greater speed and flexibility” if they so choose, while potentially avoiding judicial challenges.

In an “In Focus” brief published by the Congressional Research Service (CRS) last week, analysts provided an overview of the different mechanisms through which scheduling actions can be implemented, noting the limitations of the process that the Biden administration initiated—and that the Trump administration has since inherited—to move cannabis from Schedule I to Schedule III of the Controlled Substances Act (CSA).

“There are two ways in which substances can be scheduled under the CSA: Congress can schedule substances by enacting legislation, or the Attorney General (in conjunction with the U.S. Department of Health and Human Services, or HHS) can schedule substances via an administrative process laid out in the CSA,” CRS said.

For this report, which is an update to an earlier analysis CRS put out last year, researchers detailed various instances where Congress has stepped in and made a scheduling decision—such as the federal legalization of hemp under the 2018 Farm Bill.

“Congress placed numerous substances in Schedules I through V when it enacted the CSA in 1970,” it says. “Since the CSA’s enactment, most subsequent scheduling changes have been made by DEA via the rulemaking process, but Congress has at times enacted legislation to schedule controlled substances or change the status of existing controlled substances.”

“There are several reasons why Congress might decide to schedule or reschedule substances via legislation,” it says. “For instance, compared to administrative scheduling, legislative scheduling may offer greater speed and flexibility.”

“Administrative scheduling under the CSA proceeds via formal rulemaking, which generally takes months or years to complete. In making scheduling decisions, DEA is required by statute to make certain findings with respect to each substance’s potential for abuse and accepted medical use,” it continues. “DEA scheduling orders (other than temporary scheduling orders) are subject to judicial review, including consideration of whether the agency properly applied the relevant statutory standards.”

To that point, it did take 11 months for HHS under the Biden administration to complete its review into cannabis and make an initial rescheduling recommendation. DEA then completed a separate review before the Justice Department formally proposed moving marijuana to Schedule III—but even then, there have been months of delay in the administrative hearing process to potentially finalize the rule.

Congress, on the other hand, could reschedule or deschedule marijuana more quickly and with a lower threat of a judicial challenge, CRS said.

“Congress is not bound by the CSA’s substantive or procedural requirements,” the report says. “This means that it can schedule a substance immediately, regardless of whether the substance meets the statutory criteria. While scheduling legislation may also be challenged in court, the scope of judicial review of legislation is typically more limited than judicial review of regulations.”

It also says legislative action “may be the only way to permanently schedule large classes of substances” such as fentanyl-related substances, given the intensive statutory requirements imposed on DEA under the CSA.

“Relatedly, the CSA provides DEA with limited options for regulating controlled substances,” CRS said. “The CSA established Schedules I-V, with each schedule carrying a defined set of regulatory controls and penalties for unauthorized activities. If DEA decides to control a substance under the CSA, it must place the substance in one of the existing schedules.”

“The agency has asserted some authority to tailor controls to specific substances, but it cannot create new schedules or implement regulations or exceptions from control that are not authorized under the CSA. If Congress wishes to regulate a controlled substance in a way that does not fit within the existing CSA framework, or allow DEA to do so, it must enact legislation.”

Additionally, the report notes that while DEA is bound to consider certain international treaty obligations when it comes to drug scheduling, those same commitments “do not prevent Congress from exercising its constitutional authority to enact new laws, even when doing so might cause the United States to violate its treaty obligations.”

Meanwhile, last month a Senate committee advanced the confirmation of Terrance Cole to become the administrator of DEA amid the ongoing review of a marijuana rescheduling proposal that he’s refused to commit to enacting.

Cole—who has previously voiced concerns about the dangers of marijuana and linked its use to higher suicide risk among youth—said he would “give the matter careful consideration after consulting with appropriate personnel within the Drug Enforcement Administration, familiarizing myself with the current status of the regulatory process, and reviewing all relevant information.”

However, during an in-person hearing before the Judiciary Committee in April, he said examining the rescheduling proposal will be “one of my first priorities” if he was confirmed for the role, saying it’s “time to move forward” on the stalled process—but again without clarifying what end result he would like to see.

“I’m not familiar exactly where we are, but I know the process has been delayed numerous times—and it’s time to move forward,” he said at the time. “I need to understand more where [agencies] are and look at the science behind it and listen to the experts and really understand where they are in the process.”

Cole also said he feels it’s appropriate to form a “working group” to look at the federal-state marijuana law disconnect in order to “stay ahead of it.”

DEA recently notified an agency judge that the proceedings are still on hold—with no future actions currently scheduled. The matter sat without action before an acting administrator, Derek Maltz, who has called cannabis a “gateway drug” and linked its use to psychosis. Maltz has since left the position.

Most Marijuana Consumers Oppose Trump’s Cannabis Actions So Far, But Rescheduling Or Legalization Could Bolster Support, Poll Shows

Photo courtesy of Chris Wallis // Side Pocket Images.

Marijuana Moment is made possible with support from readers. If you rely on our cannabis advocacy journalism to stay informed, please consider a monthly Patreon pledge.

Become a patron at Patreon!





Source link

mscannabiz.com
Author: mscannabiz.com

MScannaBIZ for all you Mississippi Cannabis News and Information.

Continue Reading

featured

Trump’s Pollster Says Texas Hemp Ban Bill Faces ‘Bipartisan Opposition’ From Voters As Governor Nears Deadline To Act

Published

on


Texas Democratic and Republican voters are unified in their opposition to a bill on the governor’s desk that would ban consumable hemp products with any trace of THC, according to a new poll from a GOP pollster affiliated with President Donald Trump.

As Gov. Greg Abbott (R) weighs the controversial proposal—which advocates and stakeholders say would effectively decimate the state’s hemp industry—the poll from the firm Fabrizio, Lee & Associates found the measure is opposed across party lines. A majority of Democrats (80 percent) and independents (66 percent), as well as a plurality of Republicans (44 percent) said they don’t want the governor to sign it.

“When given a head-to-head choice, 7-in-10 Texas voters say they want hemp-derived consumable THC to remain legal in Texas with strict regulations like age restrictions and warning labels, while only 16 percent want it to be banned outright,” the polling memo says. “Republicans want hemp to remain legal by a substantial 59 percent-23 percent margin, with even bigger shares of Independents and Democrats choosing remain legal with regulations over an outright ban.”

In addition to the 59 percent of GOP voters who want hemp to stay legal in a separate question, 83 percent of Democrats and 73 percent of independents said the same.

There was notably high awareness of the bill among voters, with 52 percent of Texans saying they’ve seen, read or heard about the hemp ban proposal.

Asked whether their understanding of the legislation made them “more or less favorable toward the Texas State Legislature,” 57 percent said it left them feeling less favorable, compared to just 6 percent who said more favorable.

“Texas voters across party lines want hemp to remain legal and clearly oppose Governor Abbott signing the bill banning hemp into law,” the polling firm said. “A narrow majority have already heard about the ban passing the state house, and it’s hurting the legislature’s image and could cost them in the ballot box. The Governor can avoid the same fate and get credit across the political spectrum by vetoing this unpopular bill.”

The survey involved interviews with 600 registered Texas voters from May 28-29, with a +/-4 percentage point margin of error.

Earlier this year, Fabrizio, Lee & Associates also polled Americans on a series of broader marijuana policy issues. Notably, it found that a majority of Republicans back cannabis rescheduling—and, notably, they’re even more supportive of allowing states to legalize marijuana without federal interference compared to the average voter.

Tony Fabrizio, the polling firm’s principal, served as pollster for Trump’s 2016 and 2024 presidential campaigns.

On the Texas hemp issue, the governor still hasn’t made a decision on the bill.

“I’ll tell you this: Listen, there are meaningful positions and concerns on both sides of the issue, and I’ll look into all of those and evaluate all of those,” he told reporters during a Q & A session on Monday following a bill signing ceremony for an unrelated measure.

That largely echoes comments Abbott made earlier this month, when he said SB 3 “is one of literally more than a thousand bills on my desk—all of which need my careful consideration and evaluation.”

Also this month, hemp advocates and stakeholders delivered more than 100,000 petition signatures asking Abbott to veto the measure. Critics of the bill have said the industry—which employs an estimated 53,000 people—would be effectively eliminated if the measure becomes law.


Marijuana Moment is tracking hundreds of cannabis, psychedelics and drug policy bills in state legislatures and Congress this year. Patreon supporters pledging at least $25/month get access to our interactive maps, charts and hearing calendar so they don’t miss any developments.


Learn more about our marijuana bill tracker and become a supporter on Patreon to get access.

Texas lawmakers legalized the sale of consumable hemp in 2019, following enactment of the 2018 federal Farm Bill that Trump signed, which legalized the plant nationwide. That’s led to an explosion of products—including edibles, drinks, vape products and cured flower—sold by an estimated 8,000 retailers.

Military veterans advocates, including Texas Veterans of Foreign Wars, have also called on the governor to veto the hemp ban, saying it “would cause irreversible harm to communities across the state.”

Farmers have also said the prohibition would devastate a key sector of the state’s agriculture industry.

Meanwhile, a recent poll commissioned the Texas Hemp Business Council (THBC) found that Texas Republican primary voters oppose the proposal to ban hemp products containing THC.

Read the polling memo on the Texas hemp ban below:

Trump’s VA Head Visits Psychedelics Research Center, Reiterating ‘Promise’ To Explore Benefits For Military Veterans

Photo courtesy of Brendan Cleak.

Marijuana Moment is made possible with support from readers. If you rely on our cannabis advocacy journalism to stay informed, please consider a monthly Patreon pledge.

Become a patron at Patreon!





Source link

mscannabiz.com
Author: mscannabiz.com

MScannaBIZ for all you Mississippi Cannabis News and Information.

Continue Reading
video1 hour ago

First cannabis license issued to Minnesota business | Video

video2 hours ago

Wichita Falls woman charged for mailing synthetic cannabis in Bibles to inmates

featured3 hours ago

Trump’s VA Head Visits Psychedelics Research Center, Reiterating ‘Promise’ To Explore Benefits For Military Veterans

video3 hours ago

Access Denied

featured4 hours ago

Lawmakers Could Reschedule Marijuana With ‘Greater Speed And Flexibility’ Than Administration Officials, Congressional Researchers Say

video4 hours ago

Aurora Cannabis reduces Q4 net loss

featured5 hours ago

Trump’s Pollster Says Texas Hemp Ban Bill Faces ‘Bipartisan Opposition’ From Voters As Governor Nears Deadline To Act

video5 hours ago

Police bodycam captures £700k cannabis raid

featured6 hours ago

Rhode Island Hemp Drinks Ban Bill Scaled Back To Instead Request Officials Make Recommendations For Intoxicating Product Rules

featured7 hours ago

Minnesota Officials Award State’s First Marijuana Business License

featured8 hours ago

Colorado Governor Grants Mass Psilocybin Pardon Following Voters’ Approval Of Psychedelics Legalization At The Ballot

featured9 hours ago

Grön, Head Change Debut Exclusive Solventless Edibles in Missouri

Mississippi Cannabis News10 hours ago

Consumable Hemp Products Illegal Without FDA Approval, Mississippi AG Says

featured10 hours ago

North Carolina Senators Advance Hemp THC Restrictions

featured11 hours ago

Texas Military Veterans Say Potential Ban On Hemp-Derived THC Could Drive Them Back To Opioids Or The Illicit Marijuana Market

featured12 hours ago

Fluence Debuts SPYDR 3: Pioneering Fixture Upgrades Output and Efficiency for Cannabis Growers

featured13 hours ago

Maine Credit Union Dropping Medical Cannabis Caregiver Accounts

featured14 hours ago

Iowa Lawmaker Surprised By Governor’s ‘Unexpected’ Veto Of Psilocybin Bill

featured15 hours ago

How To Avoid Post Cannabis Grogginess

featured16 hours ago

Minnesota Adult-Use Dispensary Island Peži Celebrates 1st Anniversary

featured17 hours ago

Cannabis consumers unhappy with Trump, poll shows (Newsletter: June 18, 2025)

featured20 hours ago

Marijuana And Drug Groups Press Meta About Shadowbanning And Censorship Of Content On Facebook And Instagram

featured21 hours ago

DEA Museum Highlights Pen That Nixon Used To Sign Modern War On Drugs Into Law

featured22 hours ago

CBD From Cannabis Could Help Reduce Alcohol Binge Drinking, Study Shows

California Cannabis Updates1 year ago

Alert: Department of Cannabis Control updates data dashboards with full data for 2023 

Breaking News1 year ago

Connecticut Appoints The US’s First Cannabis Ombudsperson – Yes there is a pun in there and I’m Sure Erin Kirk Is Going To Hear It More Than Once!

best list11 months ago

5 best CBD creams of 2024 by Leafly

Bay Smokes12 months ago

Free delta-9 gummies from Bay Smokes

Business9 months ago

EU initiative begins bid to open access to psychedelic therapies

cbd1 year ago

New Study Analyzes the Effects of THCV, CBD on Weight Loss

Mississippi Cannabis News1 year ago

Mississippi city official pleads guilty to selling fake CBD products

Breaking News1 year ago

Curaleaf Start Process Of Getting Their Claws Into The UK’s National Health System – With Former MP (Resigned Today 30/5/24) As The Front Man

California1 year ago

May 2024 Leafly HighLight: Pink Runtz strain

Mississippi Cannabis News1 year ago

Horn Lake denies cannabis dispensary request to allow sale of drug paraphernalia and Sunday sales | News

autoflower seeds9 months ago

5 best autoflower seed banks of 2024 by Leafly

cannabis brands9 months ago

Discover New York’s dankest cannabis brands [September 2024]

Hemp1 year ago

Press Release: CANNRA Calls for Farm Bill to Clarify Existing State Authority to Regulate Hemp Products

Mississippi Cannabis News1 year ago

Local medical cannabis dispensary reacts to MSDH pulling Rapid Analytics License – WLBT

Breaking News1 year ago

Nevada CCB to Accept Applications for Cannabis Establishments in White Pine County – “Only one cultivation and one production license will be awarded in White Pine County”

Arkansas9 months ago

The Daily Hit: October 2, 2024

best list1 year ago

6 best CBD gummies of 2024 by Leafly

best list12 months ago

5 best THC drinks of 2024 by Leafly

best list12 months ago

5 best delta-9 THC gummies of 2024 by Leafly

Breaking News1 year ago

Weekly Update: Monday, May 13, 2024 including, New Guide for Renewals & May Board meeting application deadline

Mississippi Cannabis News1 year ago

People In This State Googled ‘Medical Marijuana’ The Most, Study Shows

Breaking News1 year ago

PRESS RELEASE : Justice Department Submits Proposed Regulation to Reschedule Marijuana

California Cannabis Updates1 year ago

Press Release: May 9, STIIIZY and Healing Urban Barrios hosted an Expungement Clinic & Second Chance Resource Fair

Asia Pacific & Australia1 year ago

Thailand: Pro-cannabis advocates rally ahead of the government’s plan to recriminalize the plant

Trending